Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00784303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00784303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2008
Completion date
March 29, 2019
Enrollment
117 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer